CSL Licenses Arcturus mRNA Technology, But COVID-19 Vaccine Remains Uncertain
The two companies signed a development and commercialization deal with a $200m upfront payment and milestones of up to $4.3bn.
You may also be interested in...
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.